Key Details
Price
$35.09Last Dividend
$0.06TTM Dividend Yield
0.51%PE Ratio
87.73Annual ROE
5.65%Beta
1.01Events Calendar
Next earnings date:
Apr 3, 2025Recent quarterly earnings:
Jan 7, 2025Recent annual earnings:
Oct 23, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Jul 29, 2024Next split:
N/ARecent split:
Oct 2, 2007Analyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Events
Dividend per share
Dividend yield
Other
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the function.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--SLP highlighted its impact on the pharma industry through support of the development of a majority of the drugs approved by the U.S. FDA in 2024.
SLP's fiscal first-quarter performance is driven by healthy revenue growth across its Software segment and contributions from the acquisition of Pro-ficiency.
Simulations Plus (SLP) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.10 per share a year ago.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenu.
SLP's fiscal first quarter performance is likely to have gained from strength in both Software and Services' segments.
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investm.
Simulations Plus (SLP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
SLP's fiscal fourth-quarter performance is driven by healthy revenue growth across its software and services business segments.
Simulations Plus, Inc. (SLP) Q4 2024 Earnings Call Transcript
FAQ
- What is the ticker symbol for Simulations Plus?
- Does Simulations Plus pay dividends?
- What sector is Simulations Plus in?
- What industry is Simulations Plus in?
- What country is Simulations Plus based in?
- When did Simulations Plus go public?
- Is Simulations Plus in the S&P 500?
- Is Simulations Plus in the NASDAQ 100?
- Is Simulations Plus in the Dow Jones?
- When was Simulations Plus's last earnings report?
- When does Simulations Plus report earnings?
- Should I buy Simulations Plus stock now?